References
- Alvandi E, Akrami SM, Chiani M, et al (2011). Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population. Thyroid, 21, 373-82. https://doi.org/10.1089/thy.2010.0267
- Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ, (2014). Cancer cachexia: understanding the molecular basis. Nat Rev Cancer, 14, 754-62. https://doi.org/10.1038/nrc3829
- Aversa Z, Bonetto A, Penna F, et al (2012). Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol,19, 1350-6. https://doi.org/10.1245/s10434-011-1720-5
- Baracos VE, (2013). Clinical Trials of Cancer Cachexia Therapy, Now and Hereafter. J Clin Oncol, 31, 1257-8. https://doi.org/10.1200/JCO.2012.48.3149
- Bonetto A, Penna F, Aversa Z, et al (2013). Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. Muscle Nerve, 48, 387-92. https://doi.org/10.1002/mus.23798
- Breitbart A, Scharf GM, Duncker D et al, (2013). Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. Plos One, 8, e80454-9. https://doi.org/10.1371/journal.pone.0080454
- Carneiro I, Castro-Piedras I, Munoz A, et al (2008). Hypothyroidism is associated with increased myostatin expression in rats. J Endocrinol Invest, 31, 773-8. https://doi.org/10.1007/BF03349256
- Ceolin L, Siqueira DR, Romitti M, Ferreira CV, Maia AL (2012). Molecular basis of medullary thyroid carcinoma: the role of RET polymorphisms. Int J Mol Sci, 13, 221-39.
- Cho YA, Kong SY, Shin A, et al (2014). Biomarkers of thyroid function and autoimmunity for predicting high-risk groups of thyroid cancer: a nested case-control study. BMC cancer, 14, 873. https://doi.org/10.1186/1471-2407-14-873
- Donohoe CL, Ryan AM, Reynolds JV, (2011). Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract, 2011,60143-4
- Elkina Y, von Haehling S, Anker SD, Springer J, (2011). The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle, 2, 143-51. https://doi.org/10.1007/s13539-011-0035-5
- Evans WJ, Morley JE, Argiles J, et al (2008). Cachexia: a new definition. Clin Nutr, 27, 793-9. https://doi.org/10.1016/j.clnu.2008.06.013
- Ghazi AA, Bagheri M, Tabibi A, Sarvghadi F, et al (2014). Multiple endocrine neoplasia type 2A in an Iranian family: clinical and genetic studies. Arch Iran Med, 17, 378-82.
- Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F (2006). Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia, 61, 564-9.
- Hedayati M, Zarif Yeganeh M, SheikholEslami S, et al (2011). Predominant RET germline mutations in exons 10, 11, and 16 in Iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res, 2011, 26424-8.
- Kern KA, Norton JA, (1988). Cancer cachexia. J Parenter Enteral Nutr, 12, 286-98. https://doi.org/10.1177/0148607188012003286
- Lokireddy S, Wijesoma IW, Bonala S, et al, (2012). Myostatin is a novel tumoral factor that induces cancer cachexia. Biochem J, 446, 23-36. https://doi.org/10.1042/BJ20112024
- Loumaye A, de Barsy M, Nachit M, et al (2015). Role of Activin A and Myostatin in human cancer cachexia. J Clin Endocrinol Metab, 100, 2030-8. https://doi.org/10.1210/jc.2014-4318
- Majidi M, Haghpanah V, Hedayati M, et al (2011). A family presenting with multiple endocrine neoplasia type 2B: A case report. J Med Case Rep, 5, 587-92. https://doi.org/10.1186/1752-1947-5-587
- McPherron AC, Lawler AM, Lee SJ, (1997). Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387, 83-90. https://doi.org/10.1038/387083a0
- Penet MF, Winnard PT Jr, Jacobs MA, et al (2011). Understanding cancer-induced cachexia: imaging the flame and its fuel. Curr Opin Support Palliat Care, 5, 327-33. https://doi.org/10.1097/SPC.0b013e32834c49ba
- Sheikholeslami S, Zarif Yeganeh M, Hoghooghi Rad L, Golab Ghadaksaz H, Hedayati M (2014). Haplotype frequency of G691S/S904S in the RET proto-onco-gene in patients with medullary thyroid carcinoma. Iran J Public Health, 43, 235-40.
- Shum AM, Polly P, (2012). Cancer cachexia: molecular targets and pathways for diagnosis and drug intervention. Endocr Metab Immune Disord Drug Targets, 12, 247-59. https://doi.org/10.2174/187153012802002910
- Smith RC, Lin BK, (2013). Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care, 7, 352-60. https://doi.org/10.1097/SPC.0000000000000013
- Tisdale MJ, (2009). Mechanisms of cancer cachexia. Physiol Rev, 89, 381-410. https://doi.org/10.1152/physrev.00016.2008
- Zarif Yeganeh M, Sheikholeslami S, Dehbashi Behbahani G, Farashi S, Hedayati M (2105). Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma. Tumour Biol, 36, 5225-31. https://doi.org/10.1007/s13277-015-3179-7
- Zarif-Yeganeh M, Sheikholeslami S, Dehbashi-Behbahani G, et al (2015). Point Mutations in RET Proto-Oncogene Exon 10 in Patients with Medullary Thyroid Carcinoma. J Kerman Univ Med Sci, 22, 249-60.
Cited by
- Evaluation of Serum Vascular Adhesion Protein-1 as a Potential Biomarker in Thyroid Cancer vol.2016, pp.1687-8345, 2016, https://doi.org/10.1155/2016/6312529